Sotatercept demonstrated statistically significant improvements in 8 of 9 secondary measures, including reduction in risk of clinical worsening or deathResults presented today at ACC.23/WCC and published in The New England Journal of MedicineRAHWAY, N.J. (BUSINESS WIRE) $MRK #MRK Merck (NYSE: MRK), known as MSD o.
Patients with pulmonary arterial hypertension (PAH), a severe, progressive condition that affects the heart and lungs, who were treated with the novel first-in-class medication sotatercept on top of existing therapy experienced significant improvements in walking distance via a six-minute walking test the study's primary endpoint and a validated surrogate for functional improvement and reduced symptom burden.
Third authorized indication in Europe for Reblozyl, a first-in-class treatment for patients with diseases impacted by anemia Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission
RAHWAY, N.J. (BUSINESS WIRE) $MRK #MRK Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the presentation of clinical data from its broad and advancing cardiovascular pipeline and portfolio at the upcoming American College of Cardiology’s 72nd Annual Scientific Session toget.
Bristol-Myers Squibb (BMY) Receives Positive CHMP Opinion for Reblozyl for Adult Patients with Anemia-Associated, NTD Beta Thalassemia streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.